Kliniken & Institute … Kliniken Radiologische Klinik … Nuklearmedizin Forschung Radiopharmazeutische… Publikationen

Publikationen & Patente

Publikationen

1. Schieck A, Schulze A, Gahler C, Muller T, Haberkorn U, Alexandrov A, Urban S, Mier W. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology. accepted;

2. Miller T, Breyer S, van Colen G, Mier W, Haberkorn U, Geissler S, Goepferich A. Premature drug release of polymeric micelles and its effects on tumor targeting. Int J Pharm. accepted;

3. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. The myristoylated preS1-domain of the hepatitis B virus L-protein mediates specific binding todifferentiated hepatocytes. Hepatology. accepted;

4. Askoxylakis V, Marr A, Altmann A, Markert A, Mier W, Debus J, Huber PE, Haberkorn U. Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Mol Imaging Biol. accepted;

5. Zoller F, Schwaebel T, Markert A, Haberkorn U, Mier W. Engineering and Functionalization of the Disulfide-Constrained Miniprotein Min-23 as a Scaffold for Diagnostic Application. Chemmedchem. 2012; 7: 237-247.

6. Zoller F, Markert A, Lindner T, Mier W, Haberkorn U. Min-23: A Promising Miniprotein Scaffold for the Design of Novel Radiopharmaceuticals Targeting Cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2012; 39: S300-S300.

7. Zoller F, Markert A, Haberkorn U, Mier W. Engineering and evaluation of a ribosome-display identified disulfide-constrained miniprotein as scaffold for molecular imaging. Journal of Peptide Science. 2012; 18: S152-S153.

8. Zoller F, Markert A, Barthe P, Zhao WY, Weichert W, Askoxylakis V, Altmann A, Mier W, Haberkorn U. Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumor-Targeting Miniproteins. Angewandte Chemie-International Edition. 2012; 51: 13136-13139.

9. Zoller F, Markert A, Barthe P, Haberkorn U, Mier W. The combination of phage display and molecular grafting gives access to a novel disulfide-stabilized miniprotein as drug candidate. Journal of Peptide Science. 2012; 18: S158-S158.

10. Sarko D, Eisenhut M, Haberkorn U, Mier W. Bifunctional Chelators in the Design and Application of Radiopharmaceuticals for Oncological Diseases. Current Medicinal Chemistry. 2012; 19: 2667-2688.

11. Rana S, Nissen F, Marr A, Markert A, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V. Optimization of a Novel Peptide Ligand Targeting Human Carbonic Anhydrase IX. Plos One. 2012; 7:

12. Raab MS, Breitkreutz I, Anderhub S, Ronnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Kramer A. GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research. 2012; 72: 5374-5385.

13. Mier W, Schieck A, Schulze A, Haberkorn U, Alexandrov A, Urban S. Safety pharmacology, pharmacokinetics and toxicology of Myrcludex B, a first-in-class hepatitis B virus entry inhibitor. Journal of Peptide Science. 2012; 18: S57-S57.

14. Michels T, Dolling R, Haberkorn U, Mier W. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis. Org Lett. 2012; 14: 5218-21.

15. Lindner T, Haberkorn U, Mier W. A novel method for regioselective disulfide formation in mini-proteins by kinetic oxidation control. Journal of Peptide Science. 2012; 18: S175-S176.

16. Jamous M, Haberkorn U, Mier W. DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA-peptide conjugates. Tetrahedron Letters. 2012; 53: 6810-6814.

17. Haefeli WE, Blank A, Mikus G, Mier W, Alexandrov A, Urban S. Successful first administration of Myrcludex B, a first-in-class Hepatitis B and D Virus entry inhibitor, in humans. Hepatology. 2012; 56: 372a-372a.

18. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M. Ga-68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry. 2012; 23: 688-697.

19. Breyer S, Semmler A, Miller T, Hill A, Geissler S, Haberkorn U, Mier W. Radioiodinated dechloro-4-iodofenofibrate: A hydrophobic model drug for molecular imaging studies. International Journal of Pharmaceutics. 2012; 431: 78-83.

20. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnolzer M, Lasischka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Na(v)1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine. 2012; 18: 926-933.

21. Zoller F, Markert A, Haberkorn U, Mier W. Molecular grafting of binding epitopes into the miniprotein scaffold Min-23 for the design of novel radiopharmaceuticals. Journal of Labelled Compounds & Radiopharmaceuticals. 2011; 54: S3-S3.

22. Zoller F, Haberkorn U, Mier W. Miniproteins as Phage Display-Scaffolds for Clinical Applications. Molecules. 2011; 16: 2467-2485.

23. Lindner T, Kolmar H, Haberkorn U, Mier W. DNA Libraries for the Construction of Phage Libraries: Statistical and Structural Requirements and Synthetic Methods. Molecules. 2011; 16: 1625-1641.

24. Kratochwil C, Lopez-Benitez R, Mier W, Haufe S, Isermann B, Kauczor HU, Choyke PL, Haberkorn U, Giesel FL. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocrine-Related Cancer. 2011; 18: 595-602.

25. Haberkorn U, Markert A, Mier W, Askoxylakis V, Altmann A. Molecular imaging of tumor metabolism and apoptosis. Oncogene. 2011; 30: 4141-4151.

26. Haberkorn U, Markert A, Eisenhut M, Mier W, Altmann A. Development of molecular techniques for imaging and treatment of tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2011; 55: 655-670.

27. Askoxylakis V, Zitzmann-Kolbe S, Zoller F, Altmann A, Markert A, Rana S, Marr A, Mier W, Debus J, Haberkorn U. Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology. Molecules. 2011; 16: 1559-1578.

28. Zoller FZ, Hauer C, Markert A, Haberkorn U, Mier W. Miniprotein engineering of the knottin-like scaffold Min-23-Fmoc-assisted synthesis and oxidative folding strategies. Journal of Peptide Science. 2010; 16: 187-187.

29. Urban S, Schulze A, Schieck A, Gahler C, Ni Y, Meier A, Alexandrov A, Mier W. Preclinical Studies on Myrcludex B, a Novel Entry Inhibitor for Hepatits B- and Hepatitis Delta Virus (Hdv) Infections. Journal of Hepatology. 2010; 52: S5-S5.

30. Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction. Journal of Virology. 2010; 84: 1989-2000.

31. Schieck AS, Muller T, Haberkorn U, Urban S, Mier W. Solid-Phase Synthesis and analytical characterization of Myrcludex B, a potent new entry inhibitor for the treatment of HBV infections. Journal of Peptide Science. 2010; 16: 127-128.

32. Schieck A, Muller T, Schulze A, Haberkorn U, Urban S, Mier W. Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor. Molecules. 2010; 15: 4773-4783.

33. Schieck A, Meier A, Alexandrov A, Leder C, Romeis P, Haberkorn U, Mier W, Urban S. Pharmacokinetic Studies on a Novel Hbv Entry Inhibitor Myrcludex B Demonstrate Hbv-Receptor Expression in Rodents and Dogs but Not in Cynomolgus Monkeys. Journal of Hepatology. 2010; 52: S387-S387.

34. Sarko D, Beijer B, Boy RG, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, Mier W. The Pharmacokinetics of Cell-Penetrating Peptides. Molecular Pharmaceutics. 2010; 7: 2224-2231.

35. Nissen F, Kraft TE, Ruppert T, Eisenhut M, Haberkorn U, Mier W. Hot or not-the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. Tetrahedron Letters. 2010; 51: 6216-6219.

36. Muller TM, Schieck A, Beijer B, Meier A, Haberkorn U, Urban S, Mier W. Exploring the HBV-envelope protein for liver-specific drug targeting. Journal of Peptide Science. 2010; 16: 34-34.

37. Mier W, Schieck A, Meier A, Muller T, Haberkorn U, Urban S. Preclinical pharmacokinetics of myrcludex B, a novel entry inhibitor for the treatment of HBV infections. Journal of Peptide Science. 2010; 16: 133-133.

38. Mier W, Kramer S, Hull WE, Eisenhut M, Haberkorn U. Solid phase synthesis and in depth analysis of the tumour targeting peptide DOTATOC for clinical applications. Journal of Peptide Science. 2010; 16: 127-127.

39. Kubas H, Schafer M, Bauder-Wust U, Eder M, Oltmanns D, Haberkorn U, Mier W, Eisenhut M. Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. Nuclear Medicine and Biology. 2010; 37: 885-891.

40. Kommera H, Kaluderovic GN, Bette M, Kalbitz J, Fuchs P, Fulda S, Mier W, Paschke R. In vitro anticancer studies of alpha- and beta-D-glucopyranose betulin anomers. Chemico-Biological Interactions. 2010; 185: 128-136.

41. Eder M, Schaefer M, Bauder-Wuest U, Schierbaum U, Leotta K, Haberkorn U, Mier W, Eisenhut M. HBED-CC- (TATE)(2): in vitro and in vivo evaluation of Octreotate dimerized by HBED-CC-TFP2. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37: S269-S269.

42. Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M. Ga-68-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37: 1397-1407.

43. Boy RG, Mier W, Nothelfer EM, Altmann A, Eisenhut M, Kolmar H, Tomaszowski M, Kramer S, Haberkorn U. Sunflower Trypsin Inhibitor 1 Derivatives as Molecular Scaffolds for the Development of Novel Peptidic Radiopharmaceuticals. Molecular Imaging and Biology. 2010; 12: 377-385.

44. Askoxylakis V, Garcia-Boy R, Rana S, Kramer S, Hebling U, Mier W, Altmann A, Markert A, Debus J, Haberkorn U. A New Peptide Ligand for Targeting Human Carbonic Anhydrase IX, Identified through the Phage Display Technology. Plos One. 2010; 5:

45. Zoller F, Eisenhut M, Haberkorn U, Mier W. Endoradiotherapy in cancer treatment - Basic concepts and future trends. European Journal of Pharmacology. 2009; 625: 55-62.

46. Oltmanns D, Eisenhut M, Mier W, Haberkorn U. Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors. Current Medicinal Chemistry. 2009; 16: 2086-2094.

47. Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Kramer S, Herold-Mende C, Altmann A, Eisenhut M, Mier W, Haberkorn U. Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer. Journal of Nuclear Medicine. 2009; 50: 426-434.

48. Haberkorn U, Eisenhut M, Altmann A, Mier W. Molecular endoradiotherapy of cancer. Minerva Biotecnologica. 2009; 21: 5-19.

49. Eder M, Schaefer M, Haberkorn U, Mier W, Eisenhut M. Hbed-Cc-Tfp2: A Versatile 68ga-Labeling Agent for Dimerization of Peptides. Journal of Labelled Compounds & Radiopharmaceuticals. 2009; 52: S478-S478.

50. Buchmann I, Meyer RG, Mier W, Haberkorn U. Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity? European Journal of Nuclear Medicine and Molecular Imaging. 2009; 36: 484-498.

51. Wangler C, Wangler B, Eisenhut M, Haberkorn U, Mier W. Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. Bioorganic & Medicinal Chemistry. 2008; 16: 2606-2616.

52. Wangler C, Moldenhauer G, Saffrich R, Knapp EM, Beijer B, Schnolzer M, Wangler B, Eisenhut M, Haberkorn U, Mier W. PAMAM Structure-Based Multifunctional Fluorescent Conjugates for Improved Fluorescent Labelling of Biomacromolecules. Chemistry-a European Journal. 2008; 14: 8116-8130.

53. Wangler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity. Bioconjugate Chemistry. 2008; 19: 813-820.

54. Schieck A, Mueller T, Boy RG, Urban S, Kunz H, Mier W. Synthesis of hepatitis B virus fusion inhibitors. Journal of Peptide Science. 2008; 14: 62-62.

55. Schieck A, Mier W, Urban S, Haberkorn U, Mueller T, Schulze A. Identification of the determinant of hepatitis B virus liver tropism and its implications for hepatocyte-specific drug targeting. Journal of Peptide Science. 2008; 14: 42-42.

56. Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). Journal of Cerebral Blood Flow and Metabolism. 2008; 28: 29-43.

57. Polonio T, Leotta K, Haberkorn U, Mier W. Failure of the development of a novel peptide tracer for molecular imaging of cancer therapy response. Journal of Peptide Science. 2008; 14: 155-156.

58. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology. 2008; 26: 335-341.

59. Kirin SI, Ott I, Gust R, Mier W, Weyhermuller T, Metzler-Nolte N. Cellular uptake quantification of metalated peptide and peptide nucleic acid bioconjugates by atomic absorption spectroscopy. Angewandte Chemie-International Edition. 2008; 47: 955-959.

60. Haberkorn U, Eisenhut M, Altmann A, Mier W. Endoradiotherapy with peptides - Status and future development. Current Medicinal Chemistry. 2008; 15: 219-234.

61. Eder M, Wangler B, Knackmuss S, LeGall F, Little M, Haberkorn U, Mier W, Eisenhut M. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for Ga-68-labeled small recombinant antibodies. European Journal of Nuclear Medicine and Molecular Imaging. 2008; 35: 1878-1886.

62. Zitzmann S, Kramer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U. Identification and evaluation of a new tumor cell-binding peptide, FROP-1. Journal of Nuclear Medicine. 2007; 48: 965-972.

63. Wolf M, Hull WE, Mier W, Heiland S, Bauder-Wust U, Kinscherf R, Haberkorn U, Eisenhut M. Polyamine-substituted gadolinium chelates: A new class of intracellular contrast agents for magnetic resonance imaging of tumors. Journal of Medicinal Chemistry. 2007; 50: 139-148.

64. Wangler C, Buchmann I, Eisenhut M, Haberkorn U, Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein and Peptide Letters. 2007; 14: 273-279.

65. Prenzel T, Altmann A, Mier W, Kramer S, Eisenhut M, Haberkorn U. Phage display for the identification of a hepatoma binding peptide. European Journal of Nuclear Medicine and Molecular Imaging. 2007; 34: S395-S395.

66. Muller-Berghaus J, Sucker A, Thoelke A, Mier W, Haberkorn U, Schadendorf D. Comparative study of two preparations of human monocyte derived dendritic cells for clinical use. Cancer Immunology Immunotherapy. 2007; 56: 421-422.

67. Mier W, Zitzmann S, Kramer S, Reed J, Knapp EM, Altmann A, Eisenhut M, Haberkorn U. Influence of chelate conjugation on a newly identified tumor-targeting peptide. Journal of Nuclear Medicine. 2007; 48: 1545-1552.

68. Kunze K, Figl A, Muller-Berghaus J, Schadendorf D, Biedenstein S, Mier W, Haberkorn U. Alpha-type-I denditric cells for immunotherapy in melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging. 2007; 34: S411-S411.

69. Kirin SI, Noor F, Metzler-Nolte N, Mier W. Manual solid-phase peptide synthesis of metallocene-peptide bioconjugates. Journal of Chemical Education. 2007; 84: 108-111.

70. Haberkorn U, Mier W, Eisenhut M, Beijer B, Altmann A. Radiolabeling and biodistribution of PKF115-584, an inhibitor of the Wnt signalling pathway. European Journal of Nuclear Medicine and Molecular Imaging. 2007; 34: S395-S395.

71. Haberkorn U, Barbro B, Altmann A, Eisenhut M, Gelovani J, Mier W. Uptake and biodistribution of the histone deacetylase inhibitor SAHA in tumor bearing animals. European Journal of Nuclear Medicine and Molecular Imaging. 2007; 34: S395-S395.

72. Graham K, Wang Q, Boy RG, Eisenhut M, Haberkorn U, Mier W. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. Journal of Pharmacy and Pharmaceutical Sciences. 2007; 10: 286-297.

73. Boy RG, Haberkorn U, Mier W. Stabilisation of small proteins for their use as pharmacological scaffolds - why knot? Chimica Oggi-Chemistry Today. 2007; 25: 37-39.

74. Askoxylakis V, Mier W, Haberkorn U, Debus J. Preclinical evaluation of a new pepticle with affinity for breast cancer cells, identified through phage display technology. Strahlentherapie Und Onkologie. 2007; 183: 100-100.

75. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W, Eisenhut M, Haberkorn U, Kinscherf R. Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. Journal of Nuclear Medicine. 2006; 47: 543-551.

76. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss L, Koczan D, Mier W, Eisenhut M, Kinscherf R, Haberkorn U. Troponin I overexpression inhibits tumor growth, perfusion, and vascularization of Morris hepatoma. Journal of Nuclear Medicine. 2006; 47: 1506-1514.

77. Sanchez OC, Mohammed A, Bauer C, Wolf M, Wangler B, Mier W, Mocelo R, Haberkorn U, Eisenhut M. Inhibiting role of aryl substituents on the aminolytic reactivity of activated Tc-99m complexes comprising a 3,4-diaminobenzoate backbone. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S302-S302.

78. Sanchez OC, Mohammed A, Bauer C, Wolf M, Wangler B, Mier W, Haberkorn U, Mocelo R, Elsenhut M. Tc-99m complexes with activated ester functions; ligands comprising a 3,4-diamino-benzoate backbone. Nuclear Medicine and Biology. 2006; 33: 381-390.

79. Petersen J, Dandri M, Lutgehetmann M, Volz T, Mier W, Haberkorn U, von Weizsacker F, Gripon P, Urban S. In vivo, inhibition of HBV infection by acylated preS peptides in the urokinase-type plasminogen activator (UPA) mouse model. Journal of Hepatology. 2006; 44: S16-S16.

80. Mier W, Urban S, Eskerski H, Petersen J, Eisenhut M, Haberkorn U. The potential of hepatitis B virus (HBV) entry inhibitors for the development of hepatotropic tracers. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S311-S311.

81. Mier W, Graham K, Kraemer S, Beck C, Eisenhut M, Haberkorn U. Multiple DOTA chelates conjugated to octreotate strongly diminish the tumour localisation. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S307-S307.

82. Kunz P, Hoffend J, Altmann A, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U, Kinscherf R. Angiopoietin-2 overexpression in Morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. Journal of Nuclear Medicine. 2006; 47: 1515-1524.

83. Kraemer S, Beck C, Eisenhut M, Haberkom U, Mier W. DOTA-oligomers for the improved derivatisation of proteins. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S308-S309.

84. Knapp E, Zitzmann S, Kramer S, Herold-Mende C, Mier W, Haberkorn U. Characterisation of hbp-1, a specific head and neck carcinoma binding peptide. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S284-S284.

85. Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W. Synthesis and characterization of HE-24.8: A polymeric contrast agent for magnetic resonance angiography. Bioconjugate Chemistry. 2006; 17: 42-51.

86. Henze M, Ozdemir-Sahin N, Hipp P, Mier W, Eisenhut M, Debus J, Haberkorn U. Comparison of diagnostic accuracy of F-18-FDG PET, I-123-MT- and Tc-99m-MIBI SPECT - Evaluation of tumour progression in irradiated low grade astrocytomas. Nuklearmedizin-Nuclear Medicine. 2006; 45: 49-56.

87. Chen LB, Altman A, Mier W, Lu HK, Zhu RS, Haberkorn U. Tc-99m-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nuclear Medicine and Biology. 2006; 33: 575-580.

88. Chen L, Altmann A, Zhu R, Guo L, Mier W, Eisenhut M, Haberkorn U. Amifostine successfully protects the kidneys after high dose [Lu-177-DOTA(0), Tyr(3)] octreotate. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S181-S181.

89. Chen L, Altmann A, Zhu R, Guo L, Mier W, Eisenhut M, Haberkorn U. Targeted radioiodine therapy of hepatoma using the sodium iodide symporter and the albumin promoter. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S375-S376.

90. Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L, Zhu R, Haberkorn U. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. Journal of Nuclear Medicine. 2006; 47: 854-862.

91. Bauer C, Bauder-Wust U, Mier W, Haberkom U, Eisenhut M. [Tc-99m] CGC-labeled peptides as caspase substrates for apoptosis imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2006; 33: S162-S162.

92. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang JB, Kramer S, Beck C, Schwab M, Eisenhut M, Haberkorn U. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. Journal of Nuclear Medicine. 2006; 47: 981-988.

93. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis N, Kramer S, Altmann A, Eisenhut I, Haberkorn U. New prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clinical Cancer Research. 2005; 11: 139-146.

94. Zitzmann S, Kramer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U. Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. Journal of Nuclear Medicine. 2005; 46: 782-785.

95. Wolf M, Bauder-Wust U, Haberkorn U, Mier W, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Research. 2005; 15: 383-391.

96. Sorg BL, Hull WE, Kliem HC, Mier W, Wiessler M. Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. Carbohydrate Research. 2005; 340: 181-189.

97. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. Journal of Clinical Investigation. 2005; 115: 2083-2098.

98. Sanchez OC, Bauer C, Mohammed A, Haberkorn U, Mier W, Eisenhut M. INFLUENCE OF ARYL SUBSTITUENTS ON THE REACTIVITY OF Tc-99m COMPLEXES OF TETRAFLUORPHENOL-3,5-DIAMINOBENZOATE DERIVATIVES. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S257-S257.

99. Mier W, Zhang J, Zitzmann S, Askoxylakis V, Bell A, McKenzie R, Eisenhut M, Haberkorn U. Pentabodies as Novel Scaffolds of Peptides Identified by Phage Display Screening: Labeling and Biodistribution. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S320-S320.

100. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U. Conjugation of DOTA using isolated phenolic active esters: The labeling and biodistribution of albumin as blood pool marker. Bioconjugate Chemistry. 2005; 16: 237-240.

101. Mier W, Hoffend J, Eisenhut M, Haberkorn U. Labeling and Biodistribution of an Angiogenin Inhibitor Identified by High Throughput Screening. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S293-S293.

102. Mier W, Graham K, Kramer S, Eisenhut M, Haberkorn U. Dota-Oligomers Conjugated to Octreotate: The Influence of the Number of Chelates on Receptor Binding and Biodistribution. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S122-S122.

103. Kraemer S, Askoxylakis V, Zhang J, Zitzmann S, Eisenhut M, Haberkorn U, Mier W. Multimeric Forms of P-160, a Peptide Identified by Phage Display. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S252-S252.

104. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R, Haberkorn U. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nuclear Medicine and Biology. 2005; 32: 287-292.

105. Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. Current Medicinal Chemistry. 2005; 12: 779-794.

106. Brix G, Schlicker A, Mier W, Peschke P, Bellemann ME. Biodistribution and pharmacokinetics of the F-19-labeled radiosensitizer 3-aminobenzamide: assessment by F-19 MR imaging. Magnetic Resonance Imaging. 2005; 23: 967-976.

107. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. Caspase-3 Substrates as Potential Apoptosis Imaging Agents. Journal of Labelled Compounds & Radiopharmaceuticals. 2005; 48: S285-S285.

108. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. I-131-labeled peptides as caspase substrates for apoptosis imaging. Journal of Nuclear Medicine. 2005; 46: 1066-1074.

109. Askoxylakis V, Zitzmann S, Mier W, Graham K, Kramer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clinical Cancer Research. 2005; 11: 6705-6712.

110. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Kramer S, Altmann A, Eisenhut M, Haberkorn U. New Peptide (Dup-1) Targets Prostate Carcinomas in Vivo. Journal of Peptide Science. 2004; 10: 168-168.

111. Wolf M, Bauder-Wust U, Mohammed A, Schonsiegel F, Mier W, Haberkorn U, Eisenhut M. Alkylating berizamides with melanoma cytotoxicity. Melanoma Research. 2004; 14: 353-360.

112. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu XX, Hoffend J, Haberkorn U, Eisenhut M, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nuclear Medicine and Biology. 2004; 31: 21-30.

113. Sieger S, Jiang SM, Kleinschmidt J, Eskerski H, Schonsiegel F, Altmann A, Mier W, Haberkorn U. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Therapy. 2004; 11: 41-51.

114. Schoensiegel F, Paschen A, Sieger S, Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D, Haberkorn U. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Therapy. 2004; 11: 408-418.

115. Mier W, Hoffend J, Schuhmacher J, Kramer S, Cermakova M, Eisenhut M, Haberkorn U. A convenient method for the modification of albumin with DOTA. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S385-S385.

116. Mier W, Graham KAN, Wang Q, Kramer S, Hoffend J, Eisenhut M, Haberkorn U. Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Letters. 2004; 45: 5453-5455.

117. Mier W, Graham KAN, Wang Q, Haberkorn U, Eisenhut M. Investigations into the C-Terminal Modification of Somataostatin Analogs. Journal of Peptide Science. 2004; 10: 140-140.

118. Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of the closo-borane mereaptoundecahydrododecaborate (BSH) to a tumour selective peptide. Zeitschrift Fur Anorganische Und Allgemeine Chemie. 2004; 630: 1258-1262.

119. Mier W, Eritja R, Haberkorn U, Eisenhut M. Tumor Selective Accmulation of Pna-Oligomers Conjugated to a Somatostatin Receptor Affine Peptide. Journal of Peptide Science. 2004; 10: 114-114.

120. Kollmar R, Mier W, Hoffend J, Schwab S. Effects of hypertonic saline on intracranial pressure and cerebral blood flow in patients with large cerebral infarcts. Stroke. 2004; 35: E195-E195.

121. Hoffend J, Mier W, Schmidt K, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U. In vivo characterization of Gallium-68-DOTA-albumin, a generator-produced PET blood-pool tracer. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S257-S258.

122. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: A receiver-operating-characteristic analysis. Journal of Nuclear Medicine. 2004; 45: 579-586.

123. Haberkorn U, Altmann A, Mier W, Eisenhut M. Impact of functional genomics and proteomics on radionuclide imaging. Seminars in Nuclear Medicine. 2004; 34: 4-22.

124. Graham KAN, Wang Q, Haberkorn U, Hoffend J, Eisenhut M, Mier W. Intercalator peptide conjugates for endoradiotherapy with Auger emitters. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S390-S390.

125. Graham KAN, Wang Q, Haberkorn U, Eisenhut M, Mier W. Synthesis and Evatluation of Intercalating Peptide Conjugates for the Endoradiotherapy. Journal of Peptide Science. 2004; 10: 140-140.

126. Graham KAN, Wang Q, Haberkorn U, Eisenhut M, Mier W. The impact of C-terminal modifications on the properties of Tyr(3)-octreotate derivatives. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S394-S394.

127. Cermakova M, Kramer S, Hoffend J, Eisenhut M, Haberkorn U, Mier W. Lipophilic Derivatives of Octrleotate for the Tumor Selective Transfection with Liposomes. Journal of Peptide Science. 2004; 10: 198-198.

128. Beiler HA, Steinorth J, Witt A, Mier W, Mohammed A, Waag KL, Zachariou Z. Impaired absorption of marked oligopeptide glycine-(131) tyrosine-glycine after successful autologous-allotopic ileal mucosa transplantation in beagles. Journal of Pediatric Surgery. 2004; 39: 1553-1557.

129. Altmann A, Eisenhut M, Mier W, Karlsson A, Haberkorn U. The Drosophila melanogaster deoxyribonucleoside kinase gene induces enhanced gemcitabine sensitivity in rat hepatoma cells. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S357-S357.

130. Zitzmann S, Askoxylakis V, Mier W, Eisenhut M, Schwab M, Haberkorn U. The peptide p160: A potential candidate for tumor imaging and radiotherapy. Journal of Nuclear Medicine. 2003; 44: 363p-364p.

131. Wang Q, Graham KA, Eisenhut M, Haberkorn U, Mier W. Evaluation of derivatives of octreotate as potential pancreas specific tracers. Journal of Nuclear Medicine. 2003; 44: 311p-311p.

132. Wagner S, Eritja R, Zuhayra M, Oberdorfer F, Mohammed A, Mier W, Haberkorn U, Eisenhut M. Synthesis and properties of radiolabeled CPTA-oligonucleotides. Journal of Labelled Compounds & Radiopharmaceuticals. 2003; 46: 175-186.

133. Schirrmacher E, Schirrmacher R, Beck C, Mier W, Trautman N, Rosch F. Synthesis of a Tyr(3)-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy. Tetrahedron Letters. 2003; 44: 9143-9145.

134. Sanchez OC, Mohammed A, Mier W, Graham K, Schuhmacher J, Arndt SO, Haberkorn U, Mocelo R, Eisenhut M. 2,3,5,6-tetrafluorophenyl N-(S-benzoylthioacetyl)glycylglycyl-p-aminobenzoate, a heterobifunctional Tc-99m ligand for precomplexed antibody labeling. Bioconjugate Chemistry. 2003; 14: 1209-1213.

135. Owen RW, Haubner R, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H. Isolation, structure elucidation and antioxidant potential of the major phenolic and flavonoid compounds in brined olive drupes. Food and Chemical Toxicology. 2003; 41: 703-717.

136. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Peptide-PNA conjugates: Targeted transport of antisense therapeutics into tumors. Angewandte Chemie-International Edition. 2003; 42: 1968-1971.

137. Graham KA, Wang Q, Eisenhut M, Haberkorn U, Mier W. Synthesis and evaluation of C-terminally modified derivatives of Tyr(3-)octreotate. Journal of Nuclear Medicine. 2003; 44: 300p-300p.

138. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Haberkorn U, Eisenhut N, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Journal of Nuclear Medicine. 2002; 43: 380p-380p.

139. Sadowski-Debbing K, Coy JF, Mier W, Hug H, Los M. Caspases - Their role in apoptosis and other physiological processes as revealed by knock-out studies. Archivum Immunologiae Et Therapiae Experimentalis. 2002; 50: 19-34.

140. Mier W, Schauer T, Haberkorn U, Eisenhut M. Conjugation of DOTA with using esters. Journal of Nuclear Medicine. 2002; 43: 377p-377p.

141. Mier W, Haberkorn U, Eisenhut M. [F-18]FLT; portrait of a proliferation marker. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29: 165-169.

142. Mier W, Beijer B, Graham K, Hull WE. Fluorescent somatostatin receptor probes for the intraoperative detection of tumor tissue with long-wavelength visible light. Bioorganic & Medicinal Chemistry. 2002; 10: 2543-2552.

143. Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Henze M, Pritzkow H, Haberkorn U, Eisenhut M. A new precursor for the radiosynthesis of [F-18]FLT. Nuclear Medicine and Biology. 2002; 29: 263-273.

144. Henze M, Mohammed A, Schlemmer H, Herfarth KK, Mier W, Eisenhut M, Debus J, Haberkorn U. Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[I-123]iodo-alpha-methyl-L-tyrosine and Tc-99m-MIBI SPET. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29: 1455-1461.

145. Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with F-18-fluorodeoxyglucose, I-123-alpha-methyl-L-tyrosine and Tc-99m-hexakis-2-methoxyisobutylisonitrile. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29: 324-330.

146. Graham KAN, Wang Q, Eisenhut M, Haberkorn U, Mier W. A general method for functionalising both the C- and N-terminals of Tyr(3)-octreotate. Tetrahedron Letters. 2002; 43: 5021-5024.

147. Eisenhut M, Mohammed A, Mier W, Schonsiegel F, Friebe M, Mahmood A, Jones AG, Haberkorn U. Melanoma uptake of Tc-99m complexes containing the N-(2-diethylaminoethyl)benzamide structural element. Journal of Medicinal Chemistry. 2002; 45: 5802-5805.

148. Renz A, Burek C, Mier W, Mozoluk M, Schulze-Osthoff K, Los M. Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer-drug treated tumor patients. Progress in Basic and Clinical Immunology. 2001; 495: 331-334.

149. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Preparation and preclinical development of tumor-targeting peptide-PNA conjugates. Journal of Nuclear Medicine. 2001; 42: 115p-115p.

150. Henze M, Schlemmer H, Herfarth K, Mohammed A, Mier W, Eisenhut M, Debus J, Haberkorn U. Differentiation of progressive low grade astrocytoma (LGA) from radiation injury (RI): Comparison of F-18-fluorodeoxyglucose (FDG), I-123-alpha-methyl-tyrosine (IMT) and Tc-99m-Mibi. Journal of Nuclear Medicine. 2001; 42: 66p-66p.

151. Henze M, Mohammed A, Mier W, Schlemmer H, Herfarth K, Debus J, Eisenhut M, Haberkorn U. Detection of tumor progression in the follow-up of irradiated low grade gliomas: Comparison of 18F-fluorodeoxyglucose PET, 123I-[alpha]-methyl-l-tyrosine spect and 99m Tc-sestamibi SPECT. European Journal of Nuclear Medicine. 2001; 28: 1082-1082.

152. Haberkorn U, Kinscherf R, Krammer PH, Mier W, Eisenhut M. Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. Nuclear Medicine and Biology. 2001; 28: 793-798.

153. Arlt VM, Bieler CA, Mier W, Wiessler M, Schmeiser HH. DNA adduct formation by the ubiquitous environmental contaminant 3-nitrobenzanthrone in rats determined by P-32-postlabeling. International Journal of Cancer. 2001; 93: 450-454.

154. Owen RW, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H. Identification of lignans as major components in the phenolic fraction of olive oil. Clinical Chemistry. 2000; 46: 976-988.

155. Owen RW, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignans and squalene. Food and Chemical Toxicology. 2000; 38: 647-659.

156. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Preparation and evaluation of tumor-targeting peptide-oligonucleotide conjugates. Bioconjugate Chemistry. 2000; 11: 855-860.

157. Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Haberkorn U, Eisenhut M. [F-18]FLT: F-18 labeling of 3-boc-1-(2-deoxy-3-O-nosyl-5-O-trityl-beta-D-lyxofuranosyl)thymine and other thymine derivatives. Journal of Nuclear Medicine. 2000; 41: 255P-+.

158. Henze M, Mohammed A, Mier W, Doll J, Nollert J, Rudat V, Dietz A, Eisenhut M, Haberkorn U. Pretreatment studies of F-18-fluorodeoxy-glucose (FDG), I-123-[alpha]-methyl-tyrosine (IMT) and Tc-99m-Sestamibi uptake in hypopharynx-/larynx-carcinomas. Journal of Nuclear Medicine. 2000; 41: 142p-142p.

159. Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, Gorgas K, Lehmann WD, Haberkorn U. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: Structure-affinity relationships, metabolic fate, and intracellular localization. Journal of Medicinal Chemistry. 2000; 43: 3913-3922.

160. Eisenhut M, Mohammed A, Mier W, Friebe M, Haberkorn U. Melanoma affine Tc-99m complexes of N-(2-diethylaminoethyl)benzamides. Journal of Nuclear Medicine. 1999; 40: 120p-121p.

161. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, Debatin KM. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Research. 1997; 57: 4956-4964.

162. Mier W, Oswald G, Tusellanger E, Lichtenthaler RN. Excess Enthalpy H-E of Binary-Mixtures Containing Alkanes, Ethanol and Ethyl-Tert - Butyl Ether (ETBE). Berichte Der Bunsen-Gesellschaft-Physical Chemistry Chemical Physics. 1995; 99: 1123-1130.

163. Mier W, Lichtenthaler RN, Roux AH, Grolier JPE. Excess Molar Heat-Capacities C-P,M(E) and Excess Molar Volumes V-M(E) of (X(1)CH(3)(CH2)(5)CH3+X(2)CH(3)C(CH3)(2)CH2CH(CH3)CH3+X(3)CH(3)C(CH3)(2)OC2H5+(1-X(1)-X(2)-X(3))C2H5OH)(1) .2. Ternary Mixtures and Prediction of Quaternary Values. Journal of Chemical Thermodynamics. 1994; 26: 1335-1348.

Patentanmeldungen

1. Hydrophobic modified peptides derived from preS-domain of hepatitis B virus and their use for liver specific targeting of pharmaceutical compns. for treating liver diseases. By Mier, Walter; Urban, Stephan; Mehrle, Stefan; Haberkorn, Uwe. From PCT Int. Appl. (2012), WO 2012107579 A1 20120816, Language: English.

2. Hydrophobic modified peptides for liver specific diagnosis. By Mier, Walter; Urban, Stephan; Mehrle, Stefan; Haberkorn, Uwe; Mueller, Thomas; Askoxylakis, Vasileios. From PCT Int. Appl. (2012), WO 2012107577 A1 20120816, Language: English.

3. Peptide ligands of carbonic anhydrase IX and their use in cancer diagnosis, imaging, targeting and therapy. By Askoxylakis, Vasileios; Haberkorn, Uwe; Altmann, Annette; Mier, Walter; Debus, Juergen. From PCT Int. Appl. (2012), WO 2012016713 A1 20120209, Language: English.

4. Conjugates of ε-polylysine with carboxyl group-carrying compounds and further conjugation for use in drug and contrast agent targeting of kidney. By Larbig, Gregor; Kuebelbeck, Armin; Mier, Walter; Beijer, Barbo; Haberkorn, Uwe. From Eur. Pat. Appl. (2011), EP 2277547 A1 20110126, Language: German.

5. Conjugates of ε-polylysine with carboxyl group-carrying compounds and further conjugation for use in drug and contrast agent targeting of kidney. By Kuebelbeck, Armin; Larbig, Gregor; Mier, Walter; Beijer, Barbro; Haberkorn, Uwe. From PCT Int. Appl. (2011), WO 2011009539 A1 20110127, Language: German.

6. Hydrophobic modified preS-derived peptides of hepatitis B virus and their use as vehicles for the specific delivery of compounds to the liver. By Mier, Walter; Haberkorn, Uwe; Urban, Stephan. From PCT Int. Appl. (2009), WO 2009092612 A1 20090730, Language: English.

7. Hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors. By Mier, Walter; Urban, Stephan. From PCT Int. Appl. (2009), WO 2009092611 A1 20090730, Language: English.

8. Hydrophobic derivatives of the pre-S antigen of hepatitis B virus and their use as viral entry inhibitors. By Mier, Walter; Urban, Stephan. From PCT Int. Appl. (2009), WO 2009092396 A1 20090730, Language: English.

9. Polyamine-substituted ligands for use as contrast agents. By Wolf, Markus; Bauder-Wust, Ulrike; Haberkorn, Uwe; Eisenhut, Michael; Mier, Walter. From U.S. Pat. Appl. Publ. (2007), US 20070202047 A1 20070830, Language: English.

10. Compounds useful for the at least bi-modal diagnostic imaging. By Kiessling, Fabian; Beijer, Barbro; Schulz, Ralf; Semmler, Wolfhard; Mier, Walter; Waengler, Bjoern. From PCT Int. Appl. (2007), WO 2007088129 A2 20070809, Language: English.

11. Use of FROP-1 peptide in diagnosis and treatment of tumors. By Zitzmann, Sabine; Mier, Walter; Kraemer, Susanne; Haberkorn, Uwe. From Eur. Pat. Appl. (2006), EP 1714978 A1 20061025, Language: English.

12. Peptide useful for diagnosis and therapy of tumors. By Zitzmann, Sabine; Peschke, Sigrid; Mahmut, Miriam; Mier, Walter; Haberkorn, Uwe. From Eur. Pat. Appl. (2005), EP 1531159 A1 20050518, Language: English.

13. Activated esters of chelating agents for radioactive and paramagnetic nuclides. By Mier, Walter; Eisenhut, Michael; Haberkorn, Uwe. From Ger. Offen. (2003), DE 10223281 A1 20030528, Language: German.

14. Labelling compounds for the simple synthesis of 3'(18F)fluoro-3'-deoxy thymidine, and a method for the production thereof. By Martin, Stefan Johannes; Eisenbarth, Joseph Antonius Maria; Wagner-Utermann, Ulrike; Eisenhut, Michael; Mier, Walter. From PCT Int. Appl. (2002), WO 2002060913 A1 20020808, Language: German.

15. Antisense oligonucleotide conjugates with somatostatin analogs for treatment of tumors associated with high leves of the somatostatin receptor. By Eisenhut, Michael; Mier, Walter; Eritia, Ramon; Haberkorn, Uwe. From Ger. Offen. (2001), DE 10006572 A1 20010823, Language: German.

16. Preparation of betulinic acid derivatives for pharmaceutical use in the treatment of neuroectodermal tumors. By Debatin, Klaus Michael; Fulda, Simone; Wiessler, Manfred; Los, Marek; Mier, Walter. From PCT Int. Appl. (2000), WO 2000024762 A1 20000504, Language: English.

17. Method for the production of a saccharide library for use in receptor affinity screening. By Wiessler, Manfred; Kliem, Christian; Mier, Walter; Menzler, Stefan. From PCT Int. Appl. (1998), WO 9816536 A1 19980423, Language: German.

18. Preparation and uses of saccharide-containing dendrimers with a cyclohexane-polyol or inositol core. By Wiessler, Manfred; Gschrey, Markus; Von der Lieth, Willi; Mier, Walter From PCT Int. Appl. (1997), WO 9748711 A1 19971224, Language: German.